Fisetin

Fisetin is a flavonol (3,3',4',7-tetrahydroxyflavone) structurally similar to quercetin (3,3',4',5,7-pentahydroxyflavone) but lacking the 5-hydroxyl group. This single structural difference produces substantially different properties: fisetin has better blood-brain barrier penetration, higher oral bioavailability in aglycone form (40-70% versus 2-10% for quercetin), and is considered the most potent natural senolytic flavonoid in comparative cellular screens. Yousefzadeh 2018 (PMID 30213834) identified fisetin as the most selective senolytic among 10 tested natural flavonoids. Quercetin is more widely studied for cardiovascular and allergy applications; fisetin is more studied for senolytic, neuroprotective, and longevity applications. Both are commonly used together in senolytic pulse protocols.

AFFIRM-LITE is a Phase 2 clinical trial at Mayo Clinic (NCT03675724) testing fisetin 20 mg/kg for 2 consecutive days monthly in frail elderly women. The protocol has become the de facto reference standard for human senolytic use of fisetin. For a 70-kg adult, 20 mg/kg for 2 days monthly corresponds to approximately 1400 mg per day for 2 consecutive days each month. Self-administration of this protocol is possible with commercial fisetin supplements and has a favorable safety profile in pilot human data. However, the protocol is investigational rather than evidence-based for specific clinical indications, and individual risk-benefit assessment (health status, goals, comedications, surgical planning) is worthwhile before implementing. Many longevity-focused individuals use this protocol; evidence for definitive clinical benefit is emerging but not yet definitive.

Yes, based on available human data. Pulse-dose senolytic protocols (20 mg/kg for 2 days monthly, approximately 1400-1600 mg per day for 2 days in adults) have been well-tolerated in pilot human studies and in ongoing Phase 2 trials. Continuous daily dosing up to 500 mg for 12 weeks has also been well-tolerated. The most commonly reported side effects are mild transient fatigue, GI discomfort, or headache on pulse days, generally self-limited. Drug interactions are fewer than for quercetin but include warfarin (monitor INR), fluoroquinolones (time-separate), tyrosine kinase inhibitor chemotherapy (specialist required), and iron supplementation (time-separate). Discontinue 2 weeks before scheduled surgery due to mild antiplatelet effect. Pregnancy safety data are limited; avoid supplementation during pregnancy without specific medical indication.

No, fisetin is effective as a standalone senolytic and is actually more potent than quercetin in comparative cellular screens. Yousefzadeh 2018 showed fisetin alone extended lifespan and improved healthspan in aged mice at 500 mg/kg every 2 weeks. However, some practitioners add quercetin 500-1000 mg during fisetin pulse days because the two flavonoids target overlapping but distinct pro-survival pathways in senescent cells, and the combination may provide broader senescent cell coverage. Adding quercetin is optional and reasonable but not required for senolytic benefit from fisetin alone. For users taking D+Q (dasatinib + quercetin) under medical supervision, fisetin can be added or used on alternating months as a complementary approach.

Strawberries are by far the richest common dietary source — approximately 160 mcg per gram, or about 24 mg per 150-gram cup of fresh strawberries. Other sources are substantially less: apples contain about 27 mcg/g (3-5 mg per medium apple), persimmons 11 mcg/g, lotus root 6 mcg/g, onions 5 mcg/g, grapes 4 mcg/g, kiwi 2 mcg/g, and cucumber and tomatoes in trace amounts. Typical Western daily dietary intake is under 1 mg — far below the 100-200 mg daily maintenance or 1400-1600 mg pulse-dose supplementation levels used in research protocols. Strawberries and apples support baseline polyphenol diversity and gut microbiota metabolism but do not substitute for supplementation if specific clinical endpoints (senolytic effect, cognitive protection, OA support) are the goal.

Preclinical evidence is strong; human clinical evidence is preliminary but building. Fisetin crosses the blood-brain barrier more efficiently than quercetin and concentrates in brain tissue. Maher 2015 (PMID 25757681) showed oral fisetin attenuated cognitive decline and reduced brain oxidative markers in APP/PS1 Alzheimer's model mice. Multiple mechanisms are relevant: Nrf2 activation, amyloid-beta aggregation inhibition, tau phosphorylation reduction through GSK-3beta modulation, neuroinflammation reduction, and senescent microglia removal. Human pilot trials in mild cognitive impairment are ongoing; Phase 2 trials in multiple cognitive aging contexts are recruiting. For brain health, typical protocols include fisetin 100-200 mg daily maintenance combined with other neuroprotective compounds (curcumin phytosome, omega-3 DHA, lion's mane, magnesium L-threonate, creatine) and consideration of monthly senolytic pulse dosing.

Fisetin phytosome is fisetin complexed with sunflower lecithin in a phytosomal delivery system, producing 3-5-fold higher plasma concentrations than standard aglycone fisetin at equivalent nominal dose. The phytosome technology increases apparent solubility and improves absorption across the intestinal epithelium. For continuous daily maintenance doses (100-200 mg), either aglycone or phytosome is acceptable; the absolute dose reaching circulation is adequate with either form. For pulse-dose senolytic protocols (1400-1600 mg per day for 2 days monthly), phytosome formulations are preferred because they achieve plasma concentrations that may be necessary for robust senolytic effect, and the higher bioavailability may improve clinical response. Price premium is moderate and worth the investment for pulse-dose users targeting senolytic endpoints.

Reasonable for individuals with age-related risk factors or interest in proactive health optimization, with appropriate context. For younger individuals (under 40) without specific age-related concerns, fisetin benefit is likely modest because senescent cell burden is low; other lifestyle interventions (exercise, sleep, nutrition, stress management) are higher-value. For individuals 50-60+ with accumulated risk factors or early age-related changes, fisetin maintenance dosing (100-200 mg daily) plus monthly senolytic pulse is a reasonable longevity-focused approach with favorable safety. The intervention works best as part of comprehensive lifestyle optimization (Mediterranean diet, regular exercise, adequate sleep, stress management, other longevity supplements as appropriate). Benefit is proactive and prophylactic rather than acute — expect to continue indefinitely rather than cycling on and off.

Yes, the combination is conceptually attractive and practiced by some longevity-focused individuals under specialist supervision. Rapamycin inhibits mTOR (an established longevity target with robust rodent lifespan extension evidence) typically at 5-10 mg weekly for non-transplant longevity use. Fisetin removes senescent cells via pulse-dose protocol monthly. The two mechanisms are complementary rather than overlapping. However, rapamycin is a prescription medication with significant considerations (immunosuppression, impaired wound healing, metabolic effects, drug interactions) that requires prescribing physician oversight, typically through concierge medicine or longevity-focused clinics. Drug interactions between rapamycin and fisetin are theoretically possible through CYP3A4 effects but clinical significance has not been characterized. Coordinate with prescribing physician.

Fisetin has a highly favorable safety profile. Most commonly reported effects are mild and transient: GI discomfort (nausea, loose stools, bloating) at doses above 1000 mg per dose, mitigated by food; headache at initiation, self-limited; mild fatigue on senolytic pulse days, possibly reflecting biological activity of senescent cell clearance. No consistent signal of hepatic, renal, or hematologic toxicity in trials up to 1500 mg daily for 14 days or continuous 500 mg daily for 12 weeks. Drug interactions are fewer than for quercetin but include warfarin (monitor INR), fluoroquinolone antibiotics (time-separate), tyrosine kinase inhibitor chemotherapy (specialist required), and iron supplementation (time-separate). Discontinue 2 weeks before scheduled surgery due to mild antiplatelet effect. Pregnancy safety at supplementation doses is uncharacterized; dietary intake through strawberries is safe. Long-term safety data from ongoing Phase 2 trials are favorable and accumulating.